The global computational pathology market is undergoing significant transformation as healthcare organizations increasingly adopt artificial intelligence (AI), machine learning (ML), digital pathology, and advanced image-analysis technologies. The growing prevalence of chronic diseases, particularly cancer, is increasing the demand for faster and more accurate diagnostic workflows. At the same time, the integration of whole-slide imaging, predictive analytics, and automated tissue analysis is enabling pathologists to process complex pathology data more efficiently and support personalized treatment decisions.

Market Size & Growth Projections

According to Grand View Research, the global computational pathology market was valued at USD 728.7 million in 2025 and is projected to expand steadily through 2033. The increasing integration of AI and ML into pathology workflows, growing investments in healthcare technologies, and rising demand for advanced diagnostic solutions are expected to support continued industry growth.

Key market values from Grand View Research:

• Market size, 2025: USD 728.7 million

• Estimated market size, 2026: USD 781.5 million

• Market forecast, 2033: USD 1,447.6 million

• CAGR, 2026–2033: 9.2%

• North America revenue share, 2025: 45.4%

The expansion of computational pathology is closely connected with the broader digitization of diagnostic laboratories. Digital pathology enables tissue slides to be converted into high-resolution digital images that can be analyzed using computational algorithms. This approach can improve diagnostic consistency, accelerate workflows, and support the development of precision medicine. 

Download a free sample copy of the Computational Pathology Market report to understand detailed coverage and inclusions in the final report

Primary Growth Drivers

Rising Prevalence of Chronic Diseases

The increasing prevalence of cancer and other chronic diseases is one of the major factors supporting computational pathology adoption. Pathologists require accurate and comprehensive pathology information to characterize diseases and support treatment decisions. Computational systems can analyze tissue images and identify patterns that may be difficult to detect through conventional manual examination.

The growing cancer burden is particularly important because computational pathology can assist with tumor detection, tissue classification, biomarker quantification, and disease prognosis. These capabilities are helping healthcare providers move toward more standardized and data-driven diagnostic processes.

Increasing Adoption of AI and Machine Learning

AI and ML are fundamentally changing pathology workflows. Machine learning algorithms can process large datasets and whole-slide images to identify tissue patterns, classify cellular structures, and quantify biomarkers.

These technologies can automate repetitive analytical tasks while allowing pathologists to focus on more complex cases. The ability to combine pathology images with other clinical and molecular information is also creating opportunities for predictive and personalized medicine.

Demand for Faster and More Accurate Diagnosis

Healthcare systems are under increasing pressure to provide accurate diagnoses while managing growing workloads. Computational pathology addresses this challenge by automating portions of image analysis and supporting standardized reporting.

Digital workflows can also facilitate remote collaboration between pathologists, enabling specialists to review cases without being physically located in the same facility. This is particularly valuable for healthcare systems facing shortages of specialized pathology professionals.

Increasing Healthcare Investment

Investment by healthcare providers, technology companies, biotechnology organizations, and pharmaceutical companies is supporting the development of advanced computational pathology platforms. These investments are encouraging innovation in AI algorithms, digital imaging, image management, and pathology workflow integration.

Key Market Trends

AI-Powered Digital Pathology

AI-powered pathology platforms are becoming increasingly important for disease detection, tissue analysis, and biomarker identification. The technology allows large volumes of pathology images to be analyzed rapidly while supporting consistent interpretation.

Companies are also developing specialized AI solutions for diseases such as prostate, breast, lung, and other cancers. These developments are expanding the clinical applications of computational pathology.

Cloud and Remote Pathology Workflows

The increasing adoption of digital pathology is supporting remote access to pathology images and analytical tools. Telepathology can enable expert consultations across geographic boundaries and improve access to specialized diagnostic expertise.

Services are expected to experience the fastest growth among components as healthcare institutions increasingly seek remote services, telepathology solutions, specialized expertise, and scalable computational pathology capabilities.

Computer Vision Innovation

Computer vision is emerging as an important technology within computational pathology. These systems can detect, segment, and classify tissue structures from whole-slide images, supporting automated tumor detection and identification of morphological biomarkers.

Grand View Research expects computer vision to witness the fastest growth during the forecast period, reflecting the increasing importance of automated visual analysis in pathology workflows. 

Key Market Segments

• The software segment dominated the industry with a 67.1% revenue share in 2025. Software solutions support digital workflows, predictive analytics, image analysis, standardized reporting, and integration with pathology systems. Increasing adoption of digital pathology scanners and whole-slide imaging is further supporting demand for computational pathology software.

• By application, disease diagnosis represented a 46.2% revenue share in 2025. Computational pathology can improve disease diagnosis by enabling automated detection of cellular abnormalities, tissue characteristics, and disease-specific patterns. Academic research is expected to witness the fastest growth as research institutions increasingly use computational tools to analyze complex biological datasets.

• By technology, machine learning accounted for a 36.0% revenue share in 2025. Machine learning applications include tissue classification, biomarker quantification, image analysis, and disease characterization. The integration of ML with multi-omics datasets is also strengthening predictive and prognostic capabilities.

• By end-use, hospitals held a 51.4% market share in 2025. Hospitals and diagnostic laboratories are major adopters because they require efficient digital slide management, AI-based image analysis, and automated reporting capabilities.

Looking for more specific insights? Customize this report to suite your business needs

Regional Breakdown

North America dominated the computational pathology market with a 45.4% revenue share in 2025. The region benefits from advanced healthcare infrastructure, high investment in clinical research, strong adoption of digital pathology, and increasing integration of AI-based diagnostic technologies.

The Asia Pacific region is expected to be the fastest-growing regional market during the forecast period. Increasing healthcare infrastructure development, digital transformation, investments in AI-enabled diagnostics, and growing demand for advanced pathology services are supporting regional expansion.

The U.S. held the largest country-level market share in 2025, supported by strong healthcare technology adoption and the presence of major pathology, medical technology, and AI companies. 

Core Industry Players

The competitive landscape includes established medical technology companies as well as specialized computational pathology and AI developers. Key companies profiled by Grand View Research include:

• Leica Biosystems Nussloch GmbH (subsidiary of Danaher)

• Hamamatsu Photonics K.K.

• Koninklijke Philips N.V.

• Olympus Corporation

• F. Hoffmann-La Roche Ltd.

• Aiforia Technologies PLC

• Epredia (3DHISTECH Ltd.)

• Visiopharm A/S

• Proscia Inc.

• Mindpeak GmbH

• Akoya Biosciences, Inc.

• Paige AI, Inc.

• CellaVision

• aetherAI

• Qritive

• IBEX Medical Analytics

• Nucleai, Inc.

Companies are focusing on AI-powered image analysis, whole-slide imaging, digital pathology platforms, workflow automation, and strategic partnerships to expand their presence in clinical diagnostics and research.